Published in Expert Opin Drug Saf on July 14, 2014
The position of strontium ranelate in today's management of osteoporosis. Osteoporos Int (2015) 0.90
Strontium- and calcium-containing, titanium-stabilised phosphate-based glasses with prolonged degradation for orthopaedic tissue engineering. J Biomater Appl (2015) 0.75
Dose-dependent Effects of Strontium Ranelate on Ovariectomy Rat Bone Marrow Mesenchymal Stem Cells and Human Umbilical Vein Endothelial Cells. Int J Biol Sci (2016) 0.75
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis (2012) 4.81
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab (2013) 1.77
Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum (2008) 1.51
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol (2011) 1.15
Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int (2013) 1.11
Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis (2008) 1.09
Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD. Osteoporos Int (2013) 1.06
Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int (2011) 0.94
Cardiovascular safety of strontium ranelate: real-life assessment in clinical practice. Osteoporos Int (2013) 0.93
Use of strontium ranelate and risk of acute coronary syndrome: cohort study. Ann Rheum Dis (2014) 0.90
A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int (2013) 0.86